|Bid||12.51 x 1800|
|Ask||24.00 x 800|
|Day's Range||16.44 - 17.04|
|52 Week Range||12.51 - 35.00|
|Beta (3Y Monthly)||1.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||32.78|
This transaction with Astellas provides us with novel payloads and CD3 binding moieties for our next wave of potent anti-cancer agents that leverage our technology, including Probody drug conjugates and Probody T cell engaging bispecifics,” said W. Michael Kavanaugh, M.D. chief scientific officer and head of research and non-clinical development at CytomX.
Hoyoung Huh, M.D., Ph.D., who has served as chairman of CytomX’s board of directors since March 2012, will retire from the board effective December 31, 2018, whereupon he will serve as a special advisor to the chief executive officer of CytomX. With Dr. Huh’s retirement, the board of directors has appointed Dr. McCarthy, CytomX’s president and chief executive officer, to serve as chairman. “On behalf of CytomX’s management and Board, I would like to thank Hoyoung for his strategic leadership and insight over the last six years,” said Sean McCarthy, D.Phil., president and chief executive officer of CytomX.
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Sean McCarthy became the CEO of CytomX Therapeutics Inc (NASDAQ:CTMX) in 2011. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...
CytomX Therapeutics, Inc. (CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform, today announced that clinical translational data from PROCLAIM-072, an ongoing Phase 1/2 trial evaluating CX-072, a Probody therapeutic targeting PD-L1, was presented as a poster this morning and will be highlighted during a rapid fire oral presentation tomorrow at the 33rd Annual Meeting of The Society for Immunotherapy of Cancer (SITC) being held in Washington DC. “These preliminary data provide additional proof-of concept for the Probody platform and build upon the clinical data we have presented to date showing that CX-072 appears to be performing as designed in patients,” said W. Michael Kavanaugh, M.D. chief scientific officer and head of research and non-clinical development at CytomX.
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -26.19% and -23.81%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the South San Francisco, California-based company said it had a loss of 53 cents. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed ...
PROCLAIM-CX-072 Clinical Translational Data Presented as Poster and Rapid-Fire Oral Presentation Company to Host Analyst and Investor Event and Webcast SOUTH SAN.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2018 -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of.
If you own shares in CytomX Therapeutics Inc (NASDAQ:CTMX) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure Read More...
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -2.94% and 29.52%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 35 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...